Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report

Amanda J Skwara; Russell J Schilder; Allison Zibelli; Norman G Rosenblum

doi:10.1016/j.gynor.2013.06.005

Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report

Gynecol Oncol Case Rep. 2013 Jul 1:6:7-9. doi: 10.1016/j.gynor.2013.06.005. eCollection 2013.

Authors

Amanda J Skwara¹, Russell J Schilder², Allison Zibelli³, Norman G Rosenblum⁴

Affiliations

¹ Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA.
² Department of Medical Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA ; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA.
³ Department of Medical Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA.
⁴ Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA.

Abstract

•44 year old woman treated with bevacizumab for metastatic epithelial ovarian cancer•The patient experienced vaginal cuff dehiscence and evisceration at 8 months post-operatively.•Metastasis at the surgical site and chronic inflammation implicated.

Keywords: Bevacizumab; Delayed evisceration; Epithelial ovarian cancer.